ReviewRadiology2022
Molecular Characterization and Therapeutic Approaches to Small Cell Lung Cancer: Imaging Implications.
Review in Radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Interpretable deep learning and radiomics for predicting the occurrence of brain metastases following prophylactic brain irradiation in small cell lung cancer.Translational lung cancer research · 2026Article
- Clinical impact and prognostic factors of early radiotherapy in limited-disease small-cell lung cancer cohort.Journal of thoracic disease · 2026Article
- Prognostic value of pretherapy CT-based Node-RADS for overall survival in extensive-stage small cell lung cancer treated with chemoimmunotherapy: a comparison with clinical N staging.Quantitative imaging in medicine and surgery · 2026Article
- Research on the Precise Differentiation of Pathological Subtypes of Non-Small Cell Lung Cancer Based onCancers · 2025Article
- Multimodal lung cancer theranostics via manganese phosphate/quercetin particle.Molecular cancer · 2025Article
- KM04416 suppressed lung adenocarcinoma progression by promoting immune infiltration.Journal of cardiothoracic surgery · 2024Article
- Synchronous double primary small cell lung cancer and invasive ductal breast carcinoma: a case report.BMC pulmonary medicine · 2024Article
- Biological clock regulation by theFrontiers in cell and developmental biology · 2024Review
- Biomarker-driven molecular imaging probes in radiotherapy.Theranostics · 2024Review
- Multisequence MRI-based radiomics nomogram for early prediction of osimertinib resistance in patients with non-small cell lung cancer brain metastases.European journal of radiology open · 2023Article
- CT radiomics model combined with clinical and radiographic features for discriminating peripheral small cell lung cancer from peripheral lung adenocarcinoma.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Small cell lung cancer (SCLC) is a highly aggressive malignancy with exceptionally poor prognosis, comprising approximately 15% of lung cancers. Emerging knowledge of the molecular and genomic landscape of SCLC and recent successful clinical applications of new systemic agents have allowed for precision oncology treatment approaches. Imaging is essential for the diagnosis, staging, and treatment monitoring of patients with SCLC. The role of imaging is increasing with the approval of new treatment agents, including immune checkpoint inhibitors, which lead to novel imaging manifestations of response and toxicities. The purpose of this state-of-the-art review is to provide the reader with the latest information about SCLC, focusing on the subtyping of this malignancy (molecular characterization) and the emerging systemic therapeutic approaches and their implications for imaging. The review will also discuss the future directions of SCLC imaging, radiomics and machine learning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.